We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Artificial Heart Tissue Developed in Vitro

By HospiMedica staff writers
Posted on 20 Mar 2006
Trials of a method to engineer blood vessels within the tissue of previously engineered heart muscle have resulted in significant improvement in the heart function of rats, according to a new study.

Researchers at the University of Michigan (Ann Arbor, USA) and the department of biomedical engineering at the University of North Carolina (Chapel Hill, USA) were successful in producing blood vessels within heart muscle tissue. More...
Three-dimensional cardiac tissue, termed "cardioids,” was engineered in vitro from a monolayer of cardiac cells. The cardioids were then sutured onto a support framework and implanted in a subcutaneous pocket in recipient rats.

Three weeks after implantation, the cardioids were recovered for in vitro force testing and histologic evaluation. The results demonstrated the presence of viable cells within the explanted cardioids and the presence of vascularization. Electron micrographs revealed the presence of large amounts of aligned contractile proteins and a high degree of intercellular connectivity. The tissue-engineered construct remained viable even after the three-week implantation period, maintaining cardiac-specific function. The study was published in the November 2005 edition of the journal Artificial Organs.

"The long-term goal of cardiac tissue engineering is to generate functional cardiac muscle in vitro,” stated lead researcher, Ravi K. Birla. "Work in this area could lead to the formation of functional heart muscle that can someday help patients with acute heart failure.”



Related Links:
University of Michigan
University of North Carolina

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.